In low flow conditions, or when the ratio contacted surface area versus blood volume is high, the events following blood contact with a foreign surface are determined by the so-called "blood-compatibility". As a rule, our blood is not compatible with any surface except our own healthy endothelium. Concerning artificial surfaces, at least two aspects of bloodincompatibility have to be considered: coagulation processes and immune response (1, 2) . In this respect, the successive events induced by blood contact can be summarized in a simple, and perhaps simplistic, model: a) within the first seconds, priming processes occur: water and ion exchanges, deposition of the most abundant proteins controlled by diffusion, followed by protein exchanges and conformational changes, resulting in triggering of coagulation and/or the immune response; b) amplification mainly occurs at the protein level, as illustrated by the coagulation cascade resulting in thrombin generation, with a positive feedback amplified by platelet activation, and the complement amplification loop resulting in generation of anaphylatoxins C3a and C5a and binding of nascent C3b onto bystander surfaces; c) macroscopically visible consequences are seen: thrombi resulting from the formation of a fibrin network anchored on platelet aggregates and stimulation of different subsets of leucocytes by C3a, C5a and their desarginated derivatives, recruitment of macrophages, formation and secretion of IL1 and aggregation of leucocytes.
Avoiding the priming events appears impossible, but control of the amplification phenomena should be attempted. Actually, the only blood-compatible surface (i.e, our own healthy endothelium) proceeds in such a way, producing substances which are secreted or remain on endothelial cell surfaces as receptors or adsorbed proteins and are locally active, for instance against the amplification cascade of coagulation (1, 3) . Similarly, in the search for artificial bloodcompatible surfaces, a pseudo-physiological approach can be the design of active surfaces able to control in situ the amplification phenomena by locally stimulating the activity of circulating specific regulatory proteins.
As the most obvious problem resulting from bloodincompatibility is formation of thrombi which can stay attached or leach the surface as emboli, the most obvious answer is the use of anticoagulant drugs.
Heparin as a model
Owing to the powerful anticoagulant action of this glycosaminoglycan when injected, heparin binding to surfaces has been the most popular approach for solving this major problem. When Gott et al. (4) introduced their graphite-benzalkonium-heparin coating, the molecular mechanisms regulating the anticoagulant activity of heparin were far from understood. High molecular weight heparin was known to aggregate platelets and numerous attempts to bind this polyanion were followed by frequently deceiving results; it was even stated that heparin should be desorbed to be active.
Concerning coagulation inhibition by soluble heparin, it has been clearly shown that this highly charged, anionic polyelectrolyte acts as a catalyst of the inactivation of thrombin (T), or some other coagulation proteases, by its major inhibitor antithrombin III (AT III). This protein binds on a specific site (5, 6) ( Fig. 1) , inducing a favourable conformational change. In the case of thrombin inhibition, this protein also binds to heparin, reacts with bound AT III, and the inactive complex is then released. There is also evidence for a second heparin cofactor (HC II) active against thrombin (7) , but it seems to be more specific for dermatan sulfate than for heparin itself.
The covalent binding of heparin to an insoluble polymer surface, by decreasing mobility of the molecule, results in a loss of accessibility for AT III and T, reducing the catalytic efficiency. Moreover, depending on the method of binding, the receptor sites for proteins can be masked or even degraded, resulting in a decrease of affinity for AT III, unfavourable conformational changes and/or lack of desorption of the T-AT III complex (8) .
Nevertheless, when active, surface-bound heparin keeps a similar mode of action as a catalyst of the reaction of AT III or HC lion the proteases they are able to inhibit. The action of surface-bound heparin on platelets is secondary to its antithrombic activity because thrombin is a very potent activator of platelets in the nanomolar range of concentration. Platelet retention on heparinized active surfaces has been demonstrated to be decreased after pretreatment by plasma or AT III (9) .
As regards the immune system of complement, soluble heparin has been demonstrated to inhibit the amplification C3 convertase by decreasing the binding of activating factor B on its receptor site on C3b (10). This action is independant of the presence of the AT III binding site of heparin but requires O-sulfation and N-substitution of the molecule (11) . This action has been demonstrated in purified systems but is decreased in the presence of plasma proteins which possess a high affinity for heparin. When bound to a surface, the anticomplementary action of heparin is also different: heparin increases the ability of the regulatory protein H to bind to C3b on the heparincoated Surface, allowing the inactivation of bound C3b by I (12) .
As a provisional conclusion, heparin can be used 652 for preparing surfaces mainly able to locally control coagulation and complement activation, providing that its active sites remain accessible to circulating control proteins. At least, it is a guide-line model for obtaining such properties.
Functional polymer surfaces
The use of heparinized surfaces is limited for the following reasons: a) ionic binding results in a gradual release of heparin, limiting its use to weeks; b) in many cases covalent binding results in a dramatic loss of activity and requires either sophisticated methods of binding for commercially available heparin or the use of the so-called stage 14 heparin, possessing a free amino-group, to keep a sufficient activity; c) the saccharidic backbone of heparin can be degraded by various chemical or biological agents, resulting in a final loss of activity; d) even if heparinized surfaces are active against coagulation, they have a poor anticomplementary action in blood, as far as this activity is required.
It appears that searching for polymer surfaces bearing functional groups able to locally control coagulation and/or complement amplification processes through their respective circulating inhibitors is definitely justified.
Antithrombogenic polymer surfaces
At the beginning of the fifties, Lovelock and Porterfield (13) observed that blood clotting was delayed in polystyrene tubings treated with sulfuric acid. Many attempts were then made by using anionic polymer coatings (14) , copolymer surfaces bearing anionic groups, or polyelectrolyte complexes (See review in ref. 15 ).
In fact, each negatively charged polymer surface is more or less directly active against thrombin or other coagulation factors by adsorption. This adsorption is necessary, but by no means sufficient, to obtain a true heparin-like activity, as defined in the previous chapter. Indeed, according to Migonney et al. (16) , such activity implies a sequence of the following events ( Fig. 2) : AT III and T diffusion from the solution to the surface, adsorption of both proteins in the appropriate conformations, reaction of the surface of tubings bearing either PSS0 3 or PSS0 2Asp, probably resulting from different conformations of AT Ilion these surfaces, despite similar affinities. Small diameter antithrombogenic tubings bearing PSS0 2Asp groups on their inner surface are currently being developed.
Heparin-like properties have also been shown on semi-synthetic anionic polysaccharides which were prepared with the purpose of obtaining heparin substitutes. For instance, derivatives of dextran bearing anionic groups such as carboxymethyl (CM) and carboxymethylbenzylamide sulfonate (CMBS), were prepared under soluble (22) and insoluble (Sephadex") (23) forms. The presence of both types of groups was necessary to obtain heparin-like properties. These inactive T-AT III complex induced by AT III adsorption, and diffusion of this complex into the solution. Several rate limiting steps can occur and control the overall reaction. Such a model is supported by suggestions of Lindon et al. (8) concerning the lack of catalytic properties of heparinized agarose which is due to the absence of desorption of the complex.
An illustration of these phenomena is given by comparison of the antithrombic activities of two functionalized polystyrene surfaces bearing either sulfonate (PSS0 3 ) or aspartic acid sulfamide groups (PSS0 2Asp) ( Fig. 3 ). As model resins in powder form, these surfaces were found to strongly delay the clotting time of blood plasma induced by thrombin when present in suspension (17) . This activity was demonstrated to be truly heparin-like because the polymer surfaces were able to catalyze the inhibition of T by AT III to different extents. In fact, PSS0 2Asp surfaces were as active in plasma as covalentlybound heparin surfaces (18) . Platelet retention, on a bead column made of this material, was also decreased in the presence of AT III (19) as did the previously cited heparinized surfaces (9) .
When compared to heparinized surfaces in purified systems, PSS0 2Asp surfaces were found to be more efficient catalysts of the inhibition of T by HC II, whereas they were less efficient through AT III. In contrast, PSS0 3 , that was already demonstrated to be less efficient than PSS0 2Asp through AT III (18) , was devoid of activity through HC II (20) , at least in the conditions used. In fact, Caix et al. (21) have shown that AT III adsorption behaviour was different on the Both surfaces were found to be activators of the human alternative complement pathway (29, 30) , but, in case of the polysaccharidic surface, specific antibodies directed against dextran were found to participate in the activation process (31) . By introducing CM groups on Sephadex, the activating capacity of the surface decreased and disappeared when one CM group was present per glucosyl unit. Analysis of the interactions between surfaces of Sephadex bearing different proportions of CM groups, and serum or complement proteins, led to the conclusion that nascent C3b can bind to these and probably to any (32) hydroxylbearing surface. However, when CM groups are present on the surface, a ternary complex is formed between bound C3b, CM groups and protein H, leading to inactivation by protein I of bound C3b and blocking of the amplification process (33) . Nevertheless, another polyanionic surface, i.e, Sephadex sulfate, has been described as an activator (34) . These apparent contradictions emphasized the necessity to reexamine the interactions between human complement and negatively charged polymer surfaces. In fact, by substituting polystyrene surfaces During hemodialysis with first-use cellulose derivatives such as Cuprophan" membranes, a peak increase in the plasma concentration of C3a antigen is always observed after 10-15 min of dialysis (25) . This increase coincides with a maximal leukopenia, with pulmonary sequestration of granulocyte microaggregates, contributing to the hypoxaemia which occurs during dialysis with complementactivating surfaces. For many reasons (26) , complement activation by artificial surfaces should be avoided.
This problem has been partially solved by using either surfaces to which nascent C3b cannot bind and form C3 convertase sites -e.g. AN69 or polysulfones -or surfaces to which C3b binding is strongly reduced by decreasing the density of receptor sites for C3b, e.g. cellulose acetate or Hernophan", Another approach could consist in binding of groups, able to control complement activation by blocking development of the amplification C3 convertase, whenever a few nascent C3b can initially bind to the surface.
Although complement proteins are well identified, the molecular mechanisms which could help in discriminating between activating, non-activating and inhibiting groups are not fully understood. Once again heparin can help us as Ariadne's clue: an activating surface like zymosan has been transformed into a non-activating one by binding on heparin, favoring the interaction of the modified surface with the inhibitor protein H versus the amplifying protein B on the surface-bound C3b site (12) . Soluble dextran derivatives substituted with CM and CMBS groups are inhibitors of complement activation (27) . Compared to heparin, they are better inhibitors in human serum, despite the fact that (and perhaps, because) they are Jess efficient towards coagulation (28) .
In order to show up some surface characteristics which could help in transforming an activating surface, like cellulose, into a non-activating one, we chose two polymer models; crosslinked in order to avoid solubilization (Fig. 4 ). The first was Sephadex", a
Anticomplementary polymer surfaces
properties were observed beyond a threshold of substitution by CM groups, contrary to PSSO s (24) . by different proportions of hydroxymethyl and sulfonate groups, it was demonstrated that no activation could be detected in case of surfaces bearing equal proportions of both groups, whereas hydroxymethylbearing surfaces were activators of complement and sulfonate-bearing surfaces consumed complement proteins through adsorption (30) .
CONCLUSIONS
In the search for blood-corroatiole .:Ill. ial surfaces, wall-bonded heparin has been successfully used to solve the problems of thrombus formation on the surface in contact with blood. Since it has been also demonstrated that heparin bound to a complementactivating surface could change it into a non-activating one, binding of heparin on polymer surfaces could be a good way of obtaining surfaces able to locally control the amplification processes of coagulation and complement activation, by increasing the activity of their respective inhibitor proteins.
Practical ways to obtain such heparinized active surfaces are not particularly obvious and, provided that they could be obtained, degradation of the saccharidic backbone of heparin is likely. Nevertheless, wall-bonded heparin is at least a good model for the design of blood compatible surfaces.
Requirements at the molecular level for obtaining antithrombogenic or anticomplementary properties, appear to be different but both types of activities are linked to the presence of polyanionic sites. By introducing anionic groups like either sulfonate and/ or some amino-acid sulfamides on a polystyrene backbone, or carboxymethyl and carboxymethyl benzylamide sulfonate on a Sephadex backbone, it was possible to obtain surfaces which were able to control coagulation by acting as catalysts of the inhibition of thrombin by antithrombin III: the socalled heparin-like surfaces. In fact, as heparin itself is not homogenous but is a class of structurally close but different molecules, heparin-like polymer is a label designating a class of materials, the common feature of them being to act on coagulation (and/or complement activation) amplification processes through the circulating inhibitors. Despite the fact that the properties exist, the relationships between physico-chemical and biological properties of polyanionic polymer surfaces are far from being understood, and the exact nature of the sites is unknown.
Many other questions concerning interactions of these surfaces with blood proteins and cells remain. Nevertheless, even if improving blood compatibility of polymer surfaces is still an exciting scientific adventure, it is no longer "chasing moonbeams".
